# Socioeconomic Burden of Cancer in Korea from 2011 to 2015

## Article information

Cancer Res Treat. 2020;52(3):896-906
Publication date (electronic) : 2020 March 18
doi : https://doi.org/10.4143/crt.2019.398
1Division of Cancer Control and Policy, National Cancer Control Institute, National Cancer Center, Goyang, Koreayang, Korea
2Department of Preventive Medicine, Kyung Hee University College of Medicine, Seoul, Korea
3Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea
4Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
Correspondence: Keeho Park, MD, PhD Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, llsandong-gu, Goyang 10408, Korea Tel: 82-31-920-2160 Fax: 82-31-920-2949 E-mail: khparkmd@ncc.re.kr
Received 2019 July 11; Accepted 2020 March 17.

## Abstract

### Purpose

Though the socioeconomic burden of cancer on patients is increasing in South Korea, there is little research regarding the type of cancer that incurs the highest costs. This study analyzed the socioeconomic burden on cancer patients from 2011 to 2015 according to sex and age.

### Materials and Methods

A prevalence-based approach was applied utilizing claim data of the National Health Insurance Service in Korea to estimate the socioeconomic burden of cancer on patients. Patients who received treatment for cancer from 2011 to 2015 were the study subjects. The total socioeconomic burden of their disease and treatment was divided into direct and indirect costs.

### Results

There was an increase of 50.7% for 5 years, from 821,525 to 1,237,739 cancer patients. The cancer costs for men and women increased $8,268.4 million to$9,469.7 million and $3,626.5 million to$4,475.6 million, respectively. Furthermore, the 50-59-year-old age group accounted for a large portion of the total disease cost. Liver, lung, stomach, and colorectal cancers created the heaviest economic burdens on patients.

### Conclusion

Overall, this study indicates new policies for cancer prevention, early detection, and post-cancer treatment management are necessary to help limit the costs associatedwith cancer, especially in the elderly, and provides a foundation for establishing cancer-related health care policies, particularly by defining those cancers with heavier disease burdens.

Keywords:

## Introduction

The incidence and mortality of cancer are rapidly increasing worldwide. According to the International Agency for Research on Cancer (IARC), there were 18.1 million new cases and 9.6 million deaths due to cancer worldwide in 2018 [1]. In the case of South Korea, the incidence of cancer has been reported since 1999, and the annual average increase in age-adjusted cancer incidence from 1999 to 2011 was 3.8%. Since 2011, although the incidence of cancer has decreased by 3.0% annually (except for a 3.1% increase between 2015 and 2016 [2]), the death rate from cancer has been steadily increasing. Based on 2017 data, cancer was still the leading cause of death in South Korea, accounting for 27.8% of all deaths. Also, the cancer mortality rate was 153.0 per 100,000 population, with a 1.4% increase from the previous year [3].

As Korea became an aged society in 2017 [4], the increase in the elderly population will lead to higher numbers of the elderly living with cancer [5]. Although new developments in cancer diagnostics and treatment have led to increases in cancer survival rates, the prevalence of cancer is still increasing [6]. The economic burden on cancer patients has been growing due to aging, increased survival rates, and increased use of medical care after diagnosis [7]. However, little is known about which type of cancer is the costliest in Korea. Likewise, it is not known what the year-to-year trends in cancer costs are in Korea.

### 5. Ethical statement

This study was approved by the Institutional Review Board of the National Cancer Center (approval No. ncc2016-0076). Informed consent from individual patients was waived as this study involves only de-identified administrative data.

## Results

The number of patients accessing medical services for cancer was 821,525 in 2011, 955,703 in 2012, 1,080,199 in 2013, 1,184,681 in 2014, and 1,237,739 in 2015, showing a continuous, upward trend of approximately 50.7% when comparing 2011 to 2015. In terms of cancer type, thyroid cancer exhibited the highest prevalence (n=189,711) in 2011, followed by stomach cancer (n=102,836), colorectal cancer (n=88,730), and breast cancer (n=88,594). In terms of prevalence by sex, in 2011, the number of female and male cancer patients was 451,427 (54.9%) and 370,098 (45.1%), respectively. In 2015, the number of female and male patients was 695,293 (56.2%) and 542,446 (43.8%), respectively. Overall, the number of female patients exceeded that of male patients each year (Table 1).

Prevalence of cancer by type in 2011-2015

The number of deaths from cancer was 71,944 in 2011, 74,214 in 2012, 75,848 in 2013, 77,137 in 2014, and 76,854 in 2015. In terms of cancer type, the mortality rate of lung cancer was the highest, at 31.8 deaths per 100,000 persons in 2011, followed by liver cancer (22.0 per 100,000), stomach cancer (19.5 per 100,000), and colorectal cancer (15.4 per 100,000). In 2015, the mortality rate was higher for lung cancer (34.1 per 100,000), unchanged for liver cancer (22.2 per 100,000), lower for stomach cancer (16.7 per 100,000), and higher for colorectal cancer (16.3 per 100,000) (Table 2).

Number of deaths due to cancer in 2011-2015

The cost for all cancer patients was $11,894.9 million in 2011,$12,735.8 million in 2012, $13,426.6 million in 2013,$13,719.0 million in 2014, and $13,945.3 million in 2015, exhibiting a steady increase from 2011-2015 of ~17% (Table 3). In 2011, the direct cost of disease was$5,054.9 million, and the indirect cost was $6,839.9 million. In 2015, the direct cost was$5,955.1 million, and the indirect cost was $7,990.2 million. Thus, the indirect cost was relatively higher than the direct cost (Fig. 1). Cost of cancer by sex in millions of US dollars for 2011-2015 Economic burden of cancer in millions of US dollars for 2011-2015. a)Direct cost=Direct medical+Non-medical costs, b)Indirect cost=Productivity+Premature death costs, c)Total cost=Direct+Indirect costs. Broken down by sex, the cost for male and female patients was$8,268.4 million and $3,626.5 million, respectively, in 2011. In 2015, the cost for men was$9,469.7 million, roughly 2.12 times the cost for women ($4,475.6 million). From 2011 to 2015, the economic burden continued to increase for both sexes (Table 3). In 2011, the most expensive cancers for men were liver cancer ($1,881.1 million), lung cancer ($1,310.2 million), stomach cancer ($1,191.8 million), and colorectal cancer ($918.4 million). This was also true in 2015: the cost of liver cancer was the highest ($2,020.3 million), followed by lung cancer ($1,538.6 million), stomach cancer ($1,167.6 million), and colorectal cancer ($1,051.9 million). The cost of colorectal cancer continued to increase from 2011 to 2015; the cost of lung cancer increased until 2013, decreased in 2014, and increased in 2015; and the cost of liver cancer increased until 2014, when it declined modestly. The cost of stomach cancer increased until 2013 and began decreasing in 2014. For women, in 2011, the cost was highest for breast cancer ($780.1 million), followed by colorectal cancer ($395.2 million), stomach cancer($359.6 million), and lung cancer($310.8 million). In 2015, the cost was highest for breast cancer ($1,044.3 million), followed by colorectal cancer ($459.0 million), lung cancer($390.1 million), and stomach cancer($379.7 million). Since 2014, lung cancer has been more economically burdensome than stomach cancer (Table 3). When costs were ranked based on age, the highest costs were incurred by those 50-59 years old ($36,464.7 million, 30.7% of all cancer costs), followed by those 40-49 years old ($2,491.1 million, 20.9%), 60-69 years old ($2,365.9 million, 19.9%), and ≥ 70 years old ($1,969.0 million, 16.6%). In 2015, those 50-59 years old accounted for the highest costs ($4,309.0 million, 30.9%), followed by those 60-69 years old ($2,853.2 million, 20.5%), ≥ 70 years old ($2,731.0 million, 19.6%), and 40-49 years old ($2,619.0 million, 18.8%) (Fig. 2). Economic burden of cancer by age group in millions of US dollars for 2011-2015. When a discount rate of 3% was applied (the standard for this study) to the indirect cost calculation, the productivity loss due to medical treatment in 2015 was$474.7 million for the economically active population of 60 years old and younger, $539.6 million for the population 64 years old and younger, and$622.2 million for the population ≥ 65 years old. The premature death cost for these age groups was $3,530.7 million,$4,671.9 million, and $7,367.9 million, respectively. For the sensitivity analysis, discount rates of 5%, 3%, and 0% were applied to calculate the economic loss due to premature death. When a discount rate of 5% was applied to each of the three age groups, the premature death cost was$3,140.6 million, $4,155.8 million, and$6,447.4 million, respectively. When no discount rate was applied (0%), the premature death cost was $4,392.1 million,$5,806.6 million, and $9,442.9 million, respectively. Thus, the premature death cost difference was$6,302.3 million, depending on to the methodology used. When a friction cost approach rather than human capital approach was used to calculate indirect costs, the premature death cost for the three age groups in 2015 was $176.0 million,$210.9 million, and $278.0 million, respectively, for the economically active populations of 60 years and younger, 64 years and younger, and 15 years and older (Table 4). Sensitivity analysis of the indirect cost of cancer in millions of US dollars for 2011-2015 ## Discussion This study estimated the socioeconomic costs for cancer patients from 2011 to 2015 using NHIS claims data. The number of patients who received medical treatment for cancer was 821,525 in 2011 and 1,237,739 in 2015, an increase of approximately 50%. From 2011 to 2015, the total annual costs for cancer patients increased by 17%, from$11,894.9 million to $13,945.3 million. Ongoing studies of the socioeconomic burden of cancer indicate that in countries that rank highly on the Human Development Index, cancer is already a leading cause of death and will soon become a major cause of death worldwide. By 2030, global cancer incidence is expected to increase by 75%, leading to an enormous increase in the economic burden of cancer [22]. The prevalence rate of cancer in Korea increased from 1,639.4 to 2,429.2 cases per 100,000 persons between 2011 and 2015, with thyroid, stomach, breast, and colorectal cancers being the four most common types, in that order. However, the economic burden of disease in 2015 was the highest for liver, lung, stomach, colorectal, and breast cancers, in that order. Thus, the most common cancers do not necessarily incur the highest costs. Indeed, from 2011 to 2015, liver cancer was the most burdensome, but it was not among the most common cancers overall. The economic burden of liver and stomach cancers has decreased since 2013, whereas the economic burden of colorectal and breast cancers has steadily increased since 2014. Although liver cancer was not one of the most common cancers between 2011 and 2015, it had the highest economic burden for men, followed by lung cancer, stomach cancer, and colorectal cancer. For women, breast cancer imparted the highest economic burden, followed by colorectal cancer, liver cancer, and stomach cancer. Thus, the economic burden of various cancers differs according to sex. It is therefore necessary to consider sex when establishing relevant policies and identify risk factors for particular cancer types in order to develop effective intervention and prevention strategies. According to Globocan 2018, lung cancer has the highest incidence and mortality rate of all cancers worldwide, and one in four women is affected by breast cancer [1]. In light of these data, the government of South Korea included lung cancer on the National Cancer Screening Program form for 2019. The economic burden of cancer among patients over 60 years old has continued to grow over time. The proportion of the total cost of cancer for patients aged 60 years and older increased from 36.4% in 2011 to 40.0% in 2015, an increase of 3.6%. This trend is thought to result from increases in life expectancy and the overall aging of the Korean population [23], combined with higher cancer survival rates due to advances in treatment [2]. Regardless of the reason, however, this finding reveals that policy interventions may be required to mitigate rising cancer costs. The indirect costs associated with cancer increased steadily from$6,839.9 million in 2011 to $7,990.2 million in 2015, an increase of approximately 16.9%. Although the socioeconomic cost of the disease varies according to the applied variable, indirect costs could also vary depending upon how the age of the productive population is defined. In the case of premature death costs, a time discount rate can be applied to calculate future costs; however, the results could vary depending on whether a human capital approach or a friction cost approach is applied. When calculating the socioeconomic burden of disease, there is considerable debate surrounding methodologies for calculating the wages of the elderly. Most studies consider those over 65 years of age as being economically inactive [10,20]. However, when recent wage and employment rate data for this group were included, the economic costs increased by 22% to 28% for males and 52% to 54% for females. Furthermore, when the elderly population was included, the productive population among all age groups increased sharply [24]; consequently, the assumption that those over 65 years of age earn no income results in underestimation of the economic burden of disease. Therefore, we used the Ministry of Employment and Labor’s raw survey data to determine the actual work status of and wages earned by men and women aged 65 years and older. The employment rate was calculated by applying the results of the survey to the actual work status of the elderly. The retirement age for public servants in Korea is 60 years [25], but not all individuals retire at that age. Therefore, in this study, three productive population groups were considered: those 60 years old and younger, those 64 years old and younger, and those 15 years old and older. Additionally, we compared the results obtained by applying time discount rates of 0%, 3%, and 5% for our sensitivity analyses. In this study, we applied the basic discount rate of 3% to the income of those aged ≥ 15 years ($13,945.3 million). The socioeconomic burden of cancer ranged from $9,570.4 million (5%, 60 years old and younger) to$16,020.3 million (0%, 15 years old and older) in 2015, a difference of 60%, depending on the methodology used.

The friction cost approach can also be applied to the indirect cost calculation, in addition to the human capital approach [26] applied in this study. The human capital approach estimates the expected income lost due to disease morbidity or premature death from the patient’s perspective, whereas the friction cost approach calculates costs from an employer’s perspective. Therefore, the friction cost approach calculates the losses incurred until the patient’s workload is reassigned or a replacement is hired [27], and it only reflects the value of the substitute employee during the friction period. The human capital approach has the limitation that the loss could be overestimated because it measures potential loss without considering the possibility of labor substitution [28]. However, the friction period can vary from 3-4 months to 22 weeks, or to 58 days based on country, occupation, and specific disease [15].

Canada, which periodically calculates the economic burden of all diseases, recently reported these costs for 2005-2008 and 2010 calculated using the friction cost approach [15]. In Canada, the cost of premature death due to cancer was $278 million in 2010. Unfortunately, there were not enough Korean data available to accurately determine a friction period in the present study; therefore, the Canadian friction period was used to calculate a friction cost of$278 million in 2015 for those ≥ 15 years of age in Korea. When defining the age of the economically active population as those under 60 years old, the friction cost was $176 million. A comparison of the friction cost for those under 60 years old to the highest cost of premature death in our study ($9,442.9 million) showed that estimated costs can vary by up to 192.8%, depending on the applied variables.

This study has several limitations. First, the data used in this study were limited. Only NHIS insurance claims data were used to calculate the cost of cancer to patients, and these data are limited because the system was created for the purpose of claims processing [29]; thus, the scope and scale of any non-benefit service items could not be determined [30]. To compensate for this limitation, non-benefit service costs were estimated using the coinsurance rate of non-benefit services based on the “Report on the Actual Status of Medical Service Cost of Health Insurance Patients,” published by the NHIS. Moreover, this study failed to consider differences in economic activities and wages earned between women and men. In the case of women, if a wider range of costs is applied by including household activities (such as childrearing) in addition to economic activities, the socioeconomic burden of cancer is expected to be higher. There are also limitations related to cost items. In this study, all other costs, including informal medical costs, were excluded from the calculations. Therefore, there were limitations in estimating the costs of purchasing assistive devices and medicines, costs of exercise and diet management, and the use of medical services, such as complementary, alternative, and traditional medicine. Follow-up studies should determine a more precise scale of costs.

Despite these limitations, this study estimated the socioeconomic burden on cancer patients from 2011 to 2015 using the latest Korean data—the NHIS claims data and Statistics Korea’s death data. The economic burden for each of 24 cancer types was also determined based on indirect cost calculations. During the period 2011 to 2015, the economic burden of cancer increased and is expected to increase further. Follow-up studies aimed at predicting the future economic burden of cancer in Korea using trend analyses could be designed based on the results of this study. The results of these follow-up studies could then be used as the basis for allocating limited health care resources and guiding the decisions of policymakers. To reduce the disease burden of cancer, it will be necessary to emphasize changes in lifestyle and promote early cancer detection and treatment [21]. Social and national efforts should continue to establish measures and policies for improving the quality of life for patients and reducing their psychological pain and economic burden.

## Acknowledgements

This work was supported by grants from the National Cancer Center, Republic of Korea (grant numbers 16103103 and 19101711).

## References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. National Cancer Center. Press release for 2016 cancer statistics [Internet] Goyang: National Cancer Center; 2019. [cited 2019 Dec 10]. Available from: https://ncc.re.kr/cancerStatsView.ncc?bbsnum=459&searchKey=total&searchValue=&pageNum=1 .
3. Statistics Korea. 2017 Statistics of causes of death Daejeon: Statistics Korea; 2018.
4. Statistics Korea. 2017 Population and housing census Daejeon: Statistics Korea; 2018.
5. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005;11:437–41.
6. Byun JY, Yoon SJ, Oh IH, Kim YA, Seo HY, Lee YH. Economic burden of colorectal cancer in Korea. J Prev Med Public Health 2014;47:84–93.
7. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20:2006–14.
8. Kim SG, Hahm MI, Choi KS, Seung NY, Shin HR, Park EC. The economic burden of cancer in Korea in 2002. Eur J Cancer Care (Engl) 2008;17:136–44.
9. Kim J, Hahm MI, Park EC, Park JH, Park JH, Kim SE, et al. Economic burden of cancer in South Korea for the year 2005. J Prev Med Public Health 2009;42:190–8.
10. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat 2015;47:387–98.
11. National Center for Health Statistics. Healthy people 2000 review, 1995-96 Hyattsville, MD: Public Health Services; 1996.
12. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42.
13. Baily MN, Garber AM, Berndt ER, Cutler DM. Health care productivity. Brookings Pap Econ Act. Microeconomics 1997;1997:143–215.
14. Institute of Medicine. Scientific opportunities and public needs: improving priority setting and public input at the National Institutes of Health Washington, DC: The National Academies Press; 1998.
15. Public Health Agency of Canada. The economic burden of illness in Canada, 2010 Ottawa, ON: Public Health Agency of Canada; 2017.
16. Vos T, Goss J, Begg S, Mann N. Projection of health care expenditure by disease: a case study from Australia New York: United Nations; 2007.
17. National Cancer Center. Annual report of cancer statistics in Korea in 2015 Goyang: National Cancer Center; 2017.
18. Health Insurance Policy Research Institute. Survey on the benefit coverage rate of National Health Insurance in 2011~2015 Wonju: National Health Insurance Service; 2012-2016.
19. Korea Health Panel Survey [Internet] Sejong: Korea Institute for Health and Social Affair; 2019. [cited 2019 Mar 7]. Available from: http://www.khp.re.kr/eng/main.do.
20. Kim YA, Oh IH, Yoon SJ, Kim HJ, Seo HY, Kim EJ, et al. The economic burden of breast cancer in Korea from 2007-2010. Cancer Res Treat 2015;47:583–90.
21. Korean Statistical Information Service. International statistical exchange rate in 2015 Daejeon: Korean Statistical Information Service; 2019.
22. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012;13:790–801.
23. United Nations. World population ageing 2017: highlights New York: United Nations; 2017.
24. Gong YH, Jo MW. Cost estimation of productivity loss of elderly over 70 due to premature mortality reflecting elderly employment in an aged society. J Health Tech Assess 2017;5:89–94.
25. Kim J, Noh JW, Park J, Huh T, Kwon YD. Association between health-related quality of life and work status in older Korean adults. Geriatr Gerontol Int 2018;18:1629–33.
26. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001;22:91–113.
27. van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010;69 Suppl 1:i89–91.
28. Pritchard C, Sculpher M. Productivity costs: principles and practice in economic evaluation London: Office of Health Economics (OHE); 2000.
29. Jung YH, Ko SJ. Estimating socioeconomic costs of five major diseases. Korean J Public Finance 2004;18:77–104.
30. Cho GJ. Clinical research using medical big data. Anesth Pain Med 2017;12:9–14.

## Article information Continued

### Fig. 1.

Economic burden of cancer in millions of US dollars for 2011-2015. a)Direct cost=Direct medical+Non-medical costs, b)Indirect cost=Productivity+Premature death costs, c)Total cost=Direct+Indirect costs.

### Fig. 2.

Economic burden of cancer by age group in millions of US dollars for 2011-2015.

### Table 1.

Prevalence of cancer by type in 2011-2015

Cancer type Prevalence (No. of cases)
Prevalence rate (per 100,000 persons)
2011 2012 2013 2014 2015 2011 2012 2013 2014 2015
Total: all patients with cancer 821,525 955,703 1,080,199 1,184,681 1,237,739 1,639.4 1,898.3 2,136.5 2,333.7 2,429.2
Male 370,098 425,252 475,855 520,228 542,446 1,475.6 1,688.3 1,882.1 2,050.2 2,130.7
Female 451,427 530,451 604,344 664,453 695,293 1,803.6 2,108.5 2,391.0 2,618.6 2,727.3
Lip, oral cavity, and pharynx 9,837 11,345 12,654 13,891 14,538 19.6 22.5 25.0 27.4 28.5
Esophagus 6,693 7,254 7,958 8,597 8,914 13.4 14.4 15.7 16.9 17.5
Stomach 102,836 119,157 134,209 147,142 149,900 205.2 236.7 265.5 289.9 294.2
Colon and rectum 88,730 104,557 117,520 128,005 132,078 177.1 207.7 232.4 252.2 259.2
Liver 53,908 57,870 61,264 64,305 66,142 107.6 114.9 121.2 126.7 129.8
Gallbladder, etc. 13,682 14,746 15,831 17,389 18,166 27.3 29.3 31.3 34.3 35.7
Pancreas 10,152 11,065 11,642 12,653 13,514 20.3 22.0 23.0 24.9 26.5
Larynx 5,160 5,745 6,344 6,797 6,891 10.3 11.4 12.5 13.4 13.5
Lung 53,630 58,994 64,425 69,623 73,392 107.0 117.2 127.4 137.2 144.0
Breast 88,594 102,950 117,583 132,084 142,123 176.8 204.5 232.6 260.2 278.9
Cervix uteri 19,578 21,797 23,996 25,737 25,778 39.1 43.3 47.5 50.7 50.6
Corpus uteri 7,578 9,142 10,749 12,140 12,949 15.1 18.2 21.3 23.9 25.4
Ovary 9,695 10,971 12,260 13,482 14,308 19.3 21.8 24.2 26.6 28.1
Prostate 37,353 44,048 50,592 56,575 60,787 74.5 87.5 100.1 111.4 119.3
Testis 960 1,156 1,354 1,521 1,648 1.9 2.3 2.7 3.0 3.2
Kidney 13,701 16,563 19,231 21,782 23,300 27.3 32.9 38.0 42.9 45.7
Bladder 18,889 21,468 23,904 26,369 27,677 37.7 42.6 47.3 51.9 54.3
Brain and CNS 9,258 9,795 10,262 10,658 10,879 18.5 19.5 20.3 21.0 21.4
Thyroid 189,711 232,852 273,130 299,967 311,584 378.6 462.5 540.2 590.9 611.5
Hodgkin lymphoma 1,230 1,464 1,626 1,795 1,838 2.5 2.9 3.2 3.5 3.6
Non-Hodgkin lymphoma 14,124 16,369 18,498 20,206 21,374 28.2 32.5 36.6 39.8 41.9
Multiple myeloma 3,948 4,585 5,042 5,647 6,119 7.9 9.1 10.0 11.1 12.0
Leukemia 12,743 14,016 15,408 16,916 18,018 25.4 27.8 30.5 33.3 35.4
Other and unspecified 49,535 57,794 64,717 71,400 75,822 98.8 114.8 128.0 140.7 148.8

CNS, central nervous system.

### Table 2.

Number of deaths due to cancer in 2011-2015

Cancer type No. of deaths
Mortality rate (per 100,000 persons)
2011 2012 2013 2014 2015 2011 2012 2013 2014 2015
Total cancer 71,944 74,214 75,848 77,137 76,854 143.6 147.4 150.0 152.0 150.8
Lip, oral cavity, and pharynx 943 1,039 1,082 1,100 1,170 1.9 2.1 2.1 2.2 2.3
Esophagus 1,517 1,413 1,463 1,552 1,531 3.0 2.8 2.9 3.1 3.0
Stomach 9,764 9,403 9,243 8,988 8,525 19.5 18.7 18.3 17.7 16.7
Colon and rectum 7,698 8,182 8,253 8,393 8,301 15.4 16.3 16.3 16.5 16.3
Liver 11,017 11,399 11,477 11,653 11,311 22.0 22.6 22.7 23.0 22.2
Gallbladder, etc. 3,713 3,708 3,802 3,955 4,211 7.4 7.4 7.5 7.8 8.3
Pancreas 4,406 4,809 4,865 5,150 5,439 8.8 9.6 9.6 10.1 10.7
Larynx 388 414 406 411 344 0.8 0.8 0.8 0.8 0.7
Lung 15,942 16,743 17,294 17,548 17,399 31.8 33.3 34.2 34.6 34.1
Breast 2,027 2,032 2,262 2,283 2,354 4.0 4.0 4.5 4.5 4.6
Cervix uteri 992 890 896 962 967 2.0 1.8 1.8 1.9 1.9
Corpus uteri 218 245 249 266 319 0.4 0.5 0.5 0.5 0.6
Ovary 909 914 1,043 1,024 1,055 1.8 1.8 2.1 2.0 2.1
Prostate 1,411 1,467 1,642 1,675 1,700 2.8 2.9 3.2 3.3 3.3
Testis 20 13 19 14 10 0.0 0.0 0.0 0.0 0.0
Kidney 838 924 944 953 952 1.7 1.8 1.9 1.9 1.9
Bladder 1,172 1,232 1,287 1,358 1,299 2.3 2.4 2.5 2.7 2.5
Brain and CNS 1,216 1,188 1,199 1,289 1,266 2.4 2.4 2.4 2.5 2.5
Thyroid 390 377 394 348 341 0.8 0.7 0.8 0.7 0.7
Hodgkin lymphoma 49 64 63 70 49 0.1 0.1 0.1 0.1 0.1
Non-Hodgkin lymphoma 1,393 1,532 1,598 1,580 1,693 2.8 3.0 3.2 3.1 3.3
Multiple myeloma 663 824 807 869 889 1.3 1.6 1.6 1.7 1.7
Leukemia 1,563 1,673 1,599 1,684 1,720 3.1 3.3 3.2 3.3 3.4
Other and unspecified 3,695 3,729 3,961 4,012 4,009 7.4 7.4 7.8 7.9 7.9

CNS, central nervous system.

### Table 3.

Cost of cancer by sex in millions of US dollars for 2011-2015

2011
2012
2013
2014
2015
Men
Women
Men
Women
Men
Women
Men
Women
Men
Women
Cost % Cost % Cost % Cost % Cost % Cost % Cost % Cost % Cost % Cost %
Total 8,268.4 100.00 3,626.5 100.00 8,810.9 100.00 3,924.9 100.00 9,224.8 100.00 4,201.8 100.00 9,315.8 100.00 4,403.2 100.00 9,469.7 100.00 4,475.6 100.00
Lip, oral cavity, and pharynx 168.7 2.04 31.3 0.86 207.4 2.35 33.2 0.85 212.9 2.31 42.2 1.00 221.2 2.37 41.7 0.95 247.0 2.61 42.5 0.95
Esophagus 199.8 2.42 9.2 0.25 193.6 2.20 10.0 0.25 215.7 2.34 10.9 0.26 231.8 2.49 11.8 0.27 230.4 2.43 10.5 0.23
Stomach 1,191.8 14.41 359.6 9.92 1,208.8 13.72 362.2 9.23 1,265.6 13.72 381.1 9.07 1,201.9 12.90 372.3 8.45 1,167.6 12.33 379.7 8.48
Colon and rectum 918.4 11.11 395.2 10.90 990.3 11.24 412.3 10.50 1,034.0 11.21 420.9 10.02 1,048.3 11.25 434.5 9.87 1,051.9 11.11 459.0 10.26
Liver 1,881.1 22.75 220.8 6.09 1,996.3 22.66 240.9 6.14 2,043.4 22.15 251.1 5.98 2,062.5 22.14 252.2 5.73 2,020.3 21.33 245.8 5.49
Gallbladder, etc. 216.2 2.61 97.9 2.70 223.4 2.54 108.0 2.75 230.6 2.50 106.0 2.52 250.3 2.69 116.9 2.65 274.2 2.90 127.1 2.84
Pancreas 354.8 4.29 107.8 2.97 388.5 4.41 122.3 3.12 417.9 4.53 130.0 3.09 423.8 4.55 144.3 3.28 458.3 4.84 153.6 3.43
Larynx 53.1 0.64 2.4 0.07 61.0 0.69 2.1 0.05 63.0 0.68 2.5 0.06 59.4 0.64 3.1 0.07 60.2 0.64 2.6 0.06
Lung 1,310.2 15.85 310.8 8.57 1,428.8 16.22 334.3 8.52 1,516.4 16.44 357.6 8.51 1,476.8 15.85 382.9 8.70 1,538.6 16.25 390.1 8.72
Breast 4.3 0.05 780.1 21.51 3.9 0.04 851.7 21.70 3.4 0.04 963.1 22.92 4.2 0.05 1,019.0 23.14 5.1 0.05 1,044.3 23.33
Cervix uteri 0 0.00 174.1 4.80 0 0.00 176.0 4.48 0 0.00 189.6 4.51 0 0.00 202.3 4.59 0 0.00 197.3 4.41
Corpus uteri 0 0.00 47.3 1.30 0 0.00 56.8 1.45 0 0.00 59.3 1.41 0 0.00 72.5 1.65 0 0.00 74.6 1.67
Ovary 0 0.00 156.0 4.30 0 0.00 170.6 4.35 0 0.00 189.4 4.51 0 0.00 197.2 4.48 0 0.00 201.9 4.51
Prostate 231.7 2.80 0 0.00 240.8 2.73 0 0.00 265.0 2.87 0 0.00 277.1 2.98 0 0.00 294.1 3.11 0 0.00
Testis 12.2 0.15 0 0.00 11.0 0.13 0 0.00 13.3 0.14 0 0.00 13.5 0.15 0 0.00 11.2 0.12 0 0.00
Kidney 131.2 1.59 29.0 0.80 151.2 1.72 31.7 0.81 150.0 1.63 32.4 0.77 154.5 1.66 36.7 0.83 170.6 1.80 37.4 0.83
Bladder 117.8 1.42 20.3 0.56 123.7 1.40 21.0 0.54 134.5 1.46 21.4 0.51 156.8 1.68 26.8 0.61 153.1 1.62 28.6 0.64
Brain and CNS 239.3 2.89 96.3 2.66 242.5 2.75 106.7 2.72 239.1 2.59 109.1 2.60 263.5 2.83 109.4 2.48 278.1 2.94 121.8 2.72
Thyroid 72.1 0.87 254.3 7.01 85.7 0.97 298.7 7.61 102.3 1.11 320.7 7.63 91.7 0.98 317.8 7.22 77.2 0.81 249.6 5.58
Hodgkin lymphoma 14.7 0.18 5.0 0.14 17.8 0.20 5.9 0.15 16.5 0.18 6.2 0.15 19.5 0.21 6.4 0.15 14.2 0.15 5.0 0.11
Non-Hodgkin lymphoma 217.2 2.63 88.7 2.44 247.0 2.80 97.3 2.48 251.0 2.72 100.5 2.39 252.6 2.71 104.1 2.36 284.8 3.01 116.4 2.60
Multiple myeloma 75.4 0.91 42.6 1.18 100.0 1.13 49.1 1.25 101.4 1.10 54.0 1.29 115.1 1.24 64.7 1.47 122.0 1.29 71.6 1.60
Leukemia 370.7 4.48 169.3 4.67 396.7 4.50 184.1 4.69 397.4 4.31 178.4 4.24 421.2 4.52 186.8 4.24 421.2 4.45 196.4 4.39
Other and unspecified 487.6 5.90 228.5 6.30 492.4 5.59 250.1 6.37 551.5 5.98 275.6 6.56 570.1 6.12 300.0 6.81 589.9 6.23 319.5 7.14

CNS, central nervous system.

### Table 4.

Sensitivity analysis of the indirect cost of cancer in millions of US dollars for 2011-2015

Year 15-60 years old
15-64 years old
≥ 15 years old
Productivity lossa) Productivity loss due to premature death
Productivity lossa) Productivity loss due to premature death
Productivity lossa) Productivity loss due to premature death
0%b) 3%b) 5%b) Friction costc) 0%b) 3%b) 5%b) Friction costc) 0%b) 3%b) 5%b) Friction costc)
2011 351.8 4,194.5 3,346.4 2,967.0 155.5 397.4 5,332.1 4,246.7 3,759.6 184.3 452.9 8,241.9 6,387.1 5,572.7 237.1
2012 419.5 4,266.8 3,411.4 3,028.0 162.3 473.5 5,507.3 4,397.4 3,898.0 192.3 542.8 8,790.5 6,818.2 5,950.9 252.5
2013 450.2 4,445.5 3,563.4 3,165.8 171.8 509.1 5,802.0 4,647.9 4,125.8 205.2 584.7 9,338.9 7,266.9 6,350.4 269.9
2014 474.1 4,420.4 3,559.4 3,168.9 176.8 535.2 5,773.6 4,647.3 4,134.4 210.1 610.6 9,184.1 7,177.1 6,284.7 272.9
2015 474.7 4,392.1 3,530.7 3,140.6 176.0 539.6 5,806.6 4,671.9 4,155.8 210.9 622.2 9,442.9 7,367.9 6,447.4 278.0
a)

Productivity loss (opportunity costs incurred due to the time spent at outpatient visits and hospitalization),

b)

% indicates the applied discount rate,

c)

The friction cost represents losses incurred by an employer during the defined friction period.